Company intelligence / Profile preview

Danatlas Pharmaceutical Inc.

Ownership: Private
Development stage: Preclinical

Overview

DAT-2645, a PARG inhibitor, received FDA approval for clinical trials and is currently in Phase 1 studies for advanced or metastatic solid tumors with BRCA1/2 mutations and/or Homologous Recombination Deficiency (HRD)

Therapeutic areas: OncologyMetabolic DisordersImmunologyRare DiseasesHematology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

DAT-2645

Beyond the preview

Go deeper on Danatlas Pharmaceutical Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Danatlas Pharmaceutical Inc..

Explore the full profile